Oxford Biomedica (LON:OXB) Stock Passes Below 200 Day Moving Average – Here’s Why

Posted by Doug Wharley on Jul 11th, 2026

Oxford Biomedica plc (LON:OXB – Get Free Report) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 663.28 and traded as low as GBX 586. Oxford Biomedica shares last traded at GBX 606.25, with a volume of 425,721 shares changing hands.

Analyst Ratings Changes

OXB has been the subject of several research analyst reports. Royal Bank Of Canada reduced their price target on shares of Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating for the company in a research report on Wednesday, June 24th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 price objective on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 600.04.

Get Our Latest Research Report on Oxford Biomedica

Oxford Biomedica Stock Up 0.2%

The company has a current ratio of 2.20, a quick ratio of 1.67 and a debt-to-equity ratio of 162.16. The business has a fifty day simple moving average of GBX 614.61 and a two-hundred day simple moving average of GBX 662.91. The company has a market cap of £739.54 million, a PE ratio of -22.70 and a beta of 1.12.

Oxford Biomedica Company Profile

(Get Free Report)

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.